We showed that the transcriptional similarity coefficient (TSC), identified comparing each patient tumor sample to responders versus non-responders, can be used to identify new pathway-based biomarkers of drug response in HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.